Phase 2, Open-label, Single Center, Prospective Study of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Combined With Nab-paclitaxel and Bevacizumab in the Second-line Treatment of Patients With Cancer of Unknown Primary (CUP)
Overview
- Phase
- Phase 2
- Intervention
- Recombinant humanized anti-PD-1 monoclonal antibody injection
- Conditions
- Cancer of Unknown Primary
- Sponsor
- Fudan University
- Enrollment
- 48
- Locations
- 1
- Primary Endpoint
- objective response rate (ORR) was assessed using RECIST1.1 and IRECIST standards.
- Last Updated
- 4 years ago
Overview
Brief Summary
This trial is a single-center, prospective, single-arm Phase II clinical study. The purpose is to evaluate the efficacy and safety of recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and bevacizumab in the second-line treatment of patients with unknown primary tumors.
Detailed Description
Recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and bevacizumab treatment, once every 3 weeks, treatment until disease progression, intolerable adverse reactions, patient death or withdrawal informed agree.After treatment, the patients was followed up every 9 weeks for follow-up treatment and survival.
Investigators
Xichun Hu
Director of department of medical oncology
Fudan University
Eligibility Criteria
Inclusion Criteria
- •The histopathologically confirmed metastasis is adenocarcinoma, squamous cell carcinoma, poorly differentiated carcinoma, poorly differentiated malignant tumor or neuroendocrine carcinoma;
- •Patients whose primary lesions cannot be found after standard evaluation prior to treatment: detailed history, physical examination, blood test, chest and pelvic CT, PET/CT (optional), endoscopy of symptomatic sites, and pathological examination;
- •Measurable lesions (RECIST 1.1 criteria);
- •Patients who have progressed after receiving first-line treatment for Carcinoma of Unknown Primary. For example, those who have received paclitaxel or docetaxel in the first-line treatment and progressed more than three months after the end of last treatment;
- •ECOG of 0-2;
- •Life expectancy\>3 months;
- •Within 7 days (including 7 days) before screening, the laboratory test data requirements: neutrophil count ≥1.5×10\^9/L, platelet count ≥90×10\^9/L, hemoglobin ≥90g/L (No blood transfusion in 14 days), serum total bilirubin ≤1.25 times the upper limit of normal (ULN); ALT and AST≤2.5 x ULN (patients with liver metastases ≤5x ULN); serum creatinine ≤1.25 x ULN
Exclusion Criteria
- •Patients who have previously been treated with albumin paclitaxel or bevacizumab or PD-1 monoclonal antibody;
- •Received any experimental drugs or anti-tumor drugs within 4 weeks prior to enrollment;
- •A history of other tumors in the past 5 years, except for cervix or basal cell carcinoma of the skin that has been cured;
- •Symptomatic brain or meningeal metastases (unless the patient receives treatment for\> 6 months, the imaging results are negative within 4 weeks before entering the study, and the clinical symptoms related to the tumor are stable at the time of entering the study).
- •NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Arms & Interventions
Single Arm
Recombinant humanized anti-PD-1 monoclonal antibody injection:200mg once every 3 weeks
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody injection
Outcomes
Primary Outcomes
objective response rate (ORR) was assessed using RECIST1.1 and IRECIST standards.
Time Frame: Approximately 24 months
ORR is defined as CR+PR